Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients

Ravishankar Ramachandran,Vivek Bhosale,Himanshu Reddy,Virendra Atam,MMA Faridi,Jalees Fatima,Vaibhav Shukla,Zaw A Khan, Hana Khan, Vikram Singh,Mahendra Pal Singh Negi,Mukesh Srivastava,Ajay Kumar Srivastava,Chandra Bhushan Tripathi,Nayan Ghosh,Nilanjana Majumdar,Raj Kamal Tripathi,Srikanta Kumar Rath,Prabhat Ranjan Mishra,Sharad Sharma

International Journal of Infectious Diseases（2022）

Cited 15|Views16

No score

Abstract

•Phase 3, Randomized, Placebo-controlled trial of Umifenovir against COVID-19•Unique dosage of 800mg BID was tested•Statistically significant endpoints achieved for Mild-asymptomatic patients•Umifenovir is efficacious for Mild-asymptomatic patients

Translated text

Key words

antiviral drug umifenovir,efficacy,placebo,double-blind,non-severe

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined